Corvus Pharmaceuticals CRVS Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
- Corvus Pharmaceuticals (CRVS) reported common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively of $8K in Q1 2026.
- How has Corvus Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively changed year-over-year?
- Corvus Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively increased by 14.3% year-over-year, from $7K to $8K.
- What is the long-term trend for Corvus Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively has grown at a 18.5% compound annual growth rate (CAGR), from $3K to $7K.
- What does common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively mean?
- This represents the par value of the common shares issued and outstanding. It is a foundational component of shareholders' equity and reflects the legal capital contributed by shareholders. While often small in dollar terms, it tracks the number of shares issued and the company's basic ownership structure.